Johnson & Johnson vs Pfizer: Which Is the Better Buy in 2026?

J&J's post-spin structure is important context. After divesting its consumer segment into Kenvue, what's left is medtech (surgical devices, orthopedics, diagnostics) and pharmaceuticals — both with strong recurring revenue characteristics. Pfizer's issue is that its COVID-era revenue was extraordinary and non-recurring, which makes comps brutal and investors skeptical about normalized earnings power. The pipeline has to prove itself on its own merits now.

The comparison became cleaner after J&J spun off its consumer division — what remains is a focused medtech and pharma business with predictable, diversified cash flow. Pfizer is navigating the other side of a COVID revenue cliff, with investors waiting to see whether its oncology pipeline can fill the gap that Paxlovid and vaccine revenue left. J&J for quality and consistency; Pfizer for a beaten-down value bet on pipeline execution.